格雷戈里吉尔伯特BOFA Merrill Lynch全球研究
格雷戈里吉尔伯特在第二年举行的第二年，“比任何覆盖空间的人更好地了解这些公司的潜力，”宣称一个倡导者。The BofA Merrill Lynch Global Research analyst highlighted his buy rating on Cephalon in March, on a price dip at $54.86, on the belief that the market was too negative about the Frazer, Pennsylvania–based biopharmaceuticals concern’s long-term prospects — especially in light of the company’s commitment to research and development, which rose from $105.4 million in the first quarter of 2010 to $122.3 million in the first quarter of this year. Less than two weeks after Gilbert pounded the table, Canada’s Valeant Pharmaceuticals International, announced that it had offered to buy Cephalon for $5.7 billion, or roughly $73 a share. The company rejected that bid but in early May announced with Teva Pharmaceutical Industries their agreement to merge; the Israel-based Teva would pay $81.50 per share, or $6.8 billion, for Cephalon. The acquisition is expected to be completed by the end of the year. Cephalon shares were trading at $80.65 in late August, for a whopping 47 percent gain that bested the sector by 40.1 percentage points.